πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 822 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10493103

Peroxide formulations and methods and applicators for using the same

Aclaris Therapeutics, Inc. Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10493151

Etanercept formulations stabilized with sodium chloride

Coherus BioSciences, Inc. Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10493038

Formulation of acoustically activatable particles having low vaporization energy and metho

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10493065

Formulations and methods of manufacturing formulations for use in colonic evacuation

RedHill Biopharma Ltd. Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10494327

Controlled release pharmaceutical formulations

United Therapeutics Corporation Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10485850

Methods for producing stable therapeutic formulations in aprotic polar solvents

XERIS PHARMACEUTICALS, INC. Β· Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10485869

Etanercept formulations stabilized with meglumine

Coherus BioSciences, Inc. Β· Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10479868

Polymeric stabilizing formulations

Nano Precision Medical, Inc. Β· Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10471148

Progesterone formulations having a desirable PK profile

Compass Therapeutics LLC Β· Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10472425

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10464992

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10456346

Cosmetic formulations for topical applications containing erythropoietin-derived molecules

ASC REGENITY LIMITED Β· Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10449185

Formulations of pimavanserin

ACADIA Pharmaceuticals Inc. Β· Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10435473

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10434167

Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing lipos

The Government of the United States, as represented by the Secretary of the Army Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10414656

Discrete carbon nanotubes with targeted oxidation levels and formulations thereof

MOLECULAR REBAR DESIGN, LLC Β· Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10406194

Powder formulation, method for preparing the same and use thereof

INFINITUS (CHINA) COMPANY LTD. Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10406160

Sustained release small molecule drug formulation

Indivior UK Limited Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10398662

GHB formulation and method for its manufacture

JAZZ PHARMA IRELAND LIMITED Β· Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10400025

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10391170

Stable anti-OSMR antibody formulation

Kiniksa Pharmaceuticals, GmbH Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376582

Buffer formulations for enhanced antibody stability

Outlook Therapeutics, Inc. Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376590

Sustained delivery formulations of risperidone compound

Indivior UK Limited Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10376588

Etanercept formulations stabilized with combinations of sugars and polyols

Coherus BioSciences, Inc. Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted